Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetics of Ceftolozane/Tazobactam in Patients With Burns

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Male and female subjects, ages 18-80 years, of all racial and ethnic origins.~2. Non-English Spanish speakers will be included in the study.~3. We are recruiting 12 patients with thermal burn injuries (percent total body surface area burned \>/= 20%). Patients will be at least five days from the date of the burn injury.~4. Patients will have central venous or arterial line access.~5. Patients will be already be receiving standard of care antimicrobial therapy for a suspected infection.~Exclusion Criteria:~1. Pregnant or nursing or unwilling to use a reliable contraception method during the study. The effects of ceftolozane and tazobactam on pregnancy are unknown. In addition, the metabolic changes that accompany pregnancy may alter the concentration-time profile of ceftolozane and tazobactam, so that the pregnancy and post-partum state would be a confounding variable.~2. Abnormal liver function tests: transaminases \>10 times upper limit of normal, Alkaline phosphatase \>5 times upper limit of normal, total bilirubin \>5 times upper limit of normal.~3. History of allergies to beta-lactam antibiotics.~4. Patients unwilling to comply with study procedures.~5. Current or previous participation within 28 days of enrollment in another research study that involves the use of medication, contrast, or any other compound that may alter blood count and/or blood chemistry (liver function, kidney function or electrolyte balance), unless waved by principal investigator (PI).~6. Donation of 450mL (one unit) of blood or more within 8 weeks (56 days) prior to study enrollment, unless waved by PI.~7. Creatinine clearance \< 30 ml/min as estimated by the Cockcroft-Gault equation.~8. Patients who are receiving piperazillin/tazobactam or have received piperacillin/tazobactam within the past 48 hours.~9. Patients who are receiving vasopressors.~10. Patients with a total body weight \< 60 kg or \> 130 kg.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- ceftolozane/tazobactam (Type: EXPERIMENTAL): One dose of 3 grams ceftolozane/tazobactam will be administered to each study participant.

Based on this trial design, predict the completion outcome and termination type (if applicable).